Daily - Go to TTD's     Chart scroller of  Breakout Stocks    -  Monday - October 18, 2021

{short description of image}

Daily - Bullish Investors  - Go To TTD Pre-Market Opening Breakout Watch  List  - Monday - February 1, 2021

Daily - Bullish Aggressive Investor - Go To TTD Quick Trade Setups (74% win rate) - Monday - February 1, 2021

Go To Prior Days TTD "Reports"

Go to Video Show - "How to Make Money With Breakout Stocks

{short description of image}

Ticker Tape Digest

Monday - February 1, 2021

By Leo Fasciocco -- TTD

   Ticker Tape Digest presents its daily stock market report containing stocks to go long as Breakout Trades, Quick Trades, or Bargain Accumulation Trades.

  We also feature stocks under Significant Accumulation that are poised to breakout.

Ticker Tape Digest's

Daily schedule guide for TTD subscribers

1. Pre-market - check Breakout Watch List and Quick Trades.

2. Morning - (11:30 - 12 A.M.) - check breakout stocks tape and breakout chart slide show.

3. Midday (1 P.M.) check TTD Midsession Report and see market video show.

4. After close (4 P.M.) check final TTD Report for day.

Trading Strategies


Aggressive Investors Bullish - "Breakout Stocks" - ideally suited for bull markets and special situation stocks. Potential for large returns. (See Performance)

Aggressive Investor Bullish-  "Quick Trade Stocks" -ideally suited for entry into top performing issues looking for a small quick profit."  (See Performance)

Conservative Investors  "Bargain Buy Trades for the Long Term."  Ideally suited for entry into top performing big cap stocks on pullbacks within overall up trend.(See Performance)


Aggressive Bearish Investors - "Breakdown Stocks" to Sell Short. Ideally suited for bear markets or market pull backs. Potential for large returns  (See Performance)

   The TTD report also contains stocks to short as  breakdown plays and as bargain (swing trade) shorts.

  Investors should  tend to try to go with a strategy that fits with the stock market's trend, unless there is a special situation play.

  TTD's Breakout Stocks - Long are most suitable for aggressive investors seeking ideal entry points into leading stocks, especially during bull markets. They can do extremely well in bull markets with gains of as much as several hundred percent.

 These stocks can also do extremely well during strong market rallies, or if they are in a industry group that is performing very well. They tend to have strong earnings outlooks and are near new-52 week, or all-time highs.

  TTD Quick Trade Stocks - Long These are leading issues that have pulled back in recent days, but could move higher soon. They are most suitable for Aggressive Investors willing to trade short term. These stocks will do extremely  well during market advances. They have about 74% win rate. During market rally sequences the win rate is even higher. The return is small 3% to 8% in just a few days.

 TTD's Bargain Buy Trades - Long - Long Term.  These are for conservative bullish Investors These long-term buys are ideally suited for entry into stocks on pull backs within overall up trend. These stocks can give a good return long-term especially during a bull market.

   TTD also presents Stocks To Sell or Sell Short. These issues are suitable for aggressive investors willing to take short positions both as trades or for longer-term plays. These stocks will do very well during bear markets or market pull backs.

  TTD's Bearish breakdown stocks to sell short. These issues have potential to fall sharply. They often show a technical breakdown and also some fundamental business problem such as weak earnings.  

 TTD's multi-media updates include a slide-show that presents charts and analysis at midsession. Some times TTD presents feature analysis on stocks and the market. TTD uses Windows Media Files. (WMV).

 TTD also presents a "Breakout Watch List" that is up dated daily. This list consists of key stocks in position to breakout. A close watch of this list can put you in the stock just as it breaks out. A good idea is to study the list and be ready to move into a stock quickly as it hits its breakpoint.

TTD often suggests using stop buy orders to enter. It is very important to buy a breakout stock as close as possible to the breakpoint. The idea is to get "elbow room" if the stock should follow through to the upside. This is very important in being successful in making big money with breakout stocks.

It is also essential to have a stop loss strategy for all stocks in which positions are taken. Not every stock will work as expected. It is important for investors to "police" their portfolios and avoid getting trapped in any bad positions.

 Quality rating of breakout  Two key factors: 1 - Stock near all-time high in price or near a 52-week high. 2 - earnings growth current year is strong. The ideal play is a stock with an Above Average Quality Rating. The stock is near a new high and will have strong earnings. TTD's other ratings are Average and Below Average.

Quote or chart

   TTD also has  special feature sections on  Educational Tips on Investing.

   To email Mr. Leo Fasciocco  leo@tickertapedigest.com.   

   For service, email Beverly Owen owen@tickertapedigest.com. TTD’s Tel: 1-480-878-8381 or 480-704-3331.

Monday - February 1, 2021

TTD's Breakout Stocks

  Stock Market Overview

Total Buy Breakouts   -  10

Quality of Breakouts -  Below Average

Stocks Screened - 12,234

Bull side -  Large list of breakouts with some good looking plays.

Stock market  -  Dow and S&P still bearish daily. Weekly and monthly market indicators holding bullish.

Comment -  Large list of breakouts with some good looking plays for aggressive bulls.

See Latest Earnings Reports -  A company that tops the Street's highest earnings estimate has potential to go higher. Key earnings beats -  None.

Stock Market Momentum

(Daily is based on a moving average)

Market (Daily)

 Market (Weekly)

 Market (Monthly)  

 Dow - Bearish

 Dow - Bullish

 Dow - Bullish

  Nasdaq - Bullish

  Nasdaq - Bullish

Nasdaq - Bullish

   S&P 500 - Bearish

  S&P 500 - Bullish

  S&P 500 - Bullish

Ticker Tape Digest's

Timely Breakout Stocks From Tape Action

(The “breakout List” gives all stocks breaking out of a base of five weeks or more. These stocks have a good chance to trend higher. However, a stop should be used to avoid those that do not work.

They are ranked according to percentage change and classified as leaders or other.

(Trading strategy: One should buy breakout stocks near breakpoint by using market order or stop buy.  They can also be bought soon after a follow through move, sometimes on an intraday pullback. )  

Today's Featured TTD Breakout Stock

Hologic Inc. (HOLX) - 82.89, up 3.16 - Breakpoint 81.63

Net To Soar 117% for Fiscal 2021 (Sept.), TTD Targets 100

      TTD's Quality Rating of Stock -  HOLX - ABOVE AVERAGE

   HOLX, based in Marlborough, Ma., makes diagnostic medical products. Annual revenues: $3.8 billion. HOLX's stock moves sharply higher Monday and breaks out from  its 5-week, cup-and-handle base.

  So far today, HOLX is trading a heavy 3.1 million shares. Its average daily volume is 2 million shares. .

  TTD suggests accumulation in anticipation of a breakout in a recent reports..

  TTD sees potential for more on the upside.

 HOLX did have a breakout earlier in the year, but then faded back.

 HOLX's stock moved higher in the morning and cleared its breakpoint line.

 The stock then trended sideways through most of the day.

 Then late in the session it pushed higher.

  In after-hours trading, HOLX has shot ahead $2.60.

  Tape Action

  HOLX's tape action shows the recent block trades.

  One can see the price for the blocks climbing from $79.73 in the prior session to as high as $83.46 Monday morning.

  A key bullish trade came in the morning when a block of 29,559 shares (duplicated) crossed at $80.90.

  That was up from  the prior block at $79.73 on 12,286 shares.

  Near the close a big block of 214,142 shares crossed at $82.89.

  That was up from  the prior block at $82.68 on 15,000 shares.


  HOLX makes diagnostics products, medical imaging systems and surgical products with an emphasis on women's health.

 The company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health.

 The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.


  HOLX's 12-month performance chart shows the stock up 56% versus a 17% gain for the stock market.

  Insiders were recent buyers using stock options at $22 to $73 a share.

 They were sellers at $70 to $74 a share.

  HOLX's long-term chart shows the stock rising from $35 in 2018 to a peak at $55 by early 2020.

  The stock fell to $26 in early 2020. It has since rallied strongly to an all-time high of  $82.89..

  HOLX's daily chart shows the stock climbing from $58 in September to a peak at $81 by January.

  The stock then put down a small base.

  It moved higher in the prior session and now on Monday breaks out

  HOLX's CCI momentum indicator is strongly bullish.

  Earnings Outlook

  This fiscal year ending in September of 2021, the Street predicts a 117% surge in net to $8.64 a share from the $3.98 the prior year.

  Analysts recently raised their estimates.

 The stock has a price-earnings ratio of just 9. That is very attractive for value-growth investors.

  Net for the next two quarters will be very strong.

  Net for the fiscal second quarter ending in March should surge 358%  to $2.61 a share from  the 57 cents the prior year.

  The highest estimate for the quarter is at $2.66 a share.

  The company beat the Street estimate the past four quarters by 72 cents a share, 85 cents, 39 cents and 3 cents.

  Then in the fiscal third quarter ending in June the Street predicts a 132% leap in net to $1.74 a share from  the 75 cents the prior year.

Strategy Opinion:   TTD is targeting HOLX for a move to $100 within the next few months, or sooner.  A protective stop can be placed near $78.

Intermediate-Term Rating:  Average.

Suitability:  Aggressive Bulls. 

                                 TTD's special research of Stock's Prior Performance:  

Breakout Success


 HOLX scored one big gain off a recent breakout.

Response to Net


 HOLX rose 10 times after 15 earnings reports.

Seasonal Success


 HOLX avg. loss 2% in Feb., loss 5.4% in March prior years.

Earnings Beats


HOLX beat Street net estimate 16 times after 20 reports.

           Stock's Prior Performance After A Breakout

Stock's % Change from Breakout to peak - prior  to cut below 50-day M/A.

Date of Breakout

Break point Price

Stocks Price Peak after Breakout - prior to cut below 50-day M/A

  Date Trade Closed


   1/6/2021       77.66      80.49      1/8/2021


   6/30/2020       54.95      73.32      8/5/2020


   1/7/2021       51.06      54.62      1/28/2020


   3/1/2017       41      45.96      5/10/2017

(In actual trading, entry and exit points could vary depending on broker execution.

Also, ideal are breakouts to a new 52-week high or better, perhaps all-time highs.)

  Stock's Long-term Chart

   Stock's Price Performance after Reporting Earnings


 Stock's Performance Chart with Quarterly Earnings Markers vs. S&P 500

Insider Buying in Green  -  Insider Selling in Red

Charts of Selected Breakout Stocks

      TTD's Quality Rating of Stock - DGX -  AVERAGE

      TTD's Quality Rating of Stock - DAVA -  BELOW AVERAGE

      TTD's Quality Rating of Stock - AHCO -  BELOW AVERAGE

      TTD's Quality Rating of Stock - ARGX -  BELOW  AVERAGE

Ticker Tape Digest’s

Stocks To “Sell or Short”

    Ticker Tape Digest’s Daily List of “Stocks To Sell or Sell Short” ranks stocks well timed to be sold immediately based on daily trading. The list can be used as an alert to reduce current long-term positions.

Shorts from tape action for Thursday -  1

Stocks Screened - 12,234

Long-Term Environment for bears: Unfavorable.

Bear Side - Just one short play. Bears be conservative.

List of Stocks To Sell or Short

TTD’s Feature Bear Play

Concert Pharmaceuticals Inc. (CNCE) - 7.50

Loss Seen This Year and Next, TTD Sees Drop to 5.50

  CNCE, based in Lexington, Ma., is a biotech firm  developing products to treat cystic fibrosis. Annual revenues: $1.1 million. CNCE's tock falls sharply Monday as one of its drugs to treat schizophrenia disappointed in tests.

  So far today, CNCE is trading a heavy 7.1 million shares, 28 times its average daily volume 227,000 shares.

  TTD sees potential for more on the downside.

  CNCE gapped lower in the morning and undercut key support.

  The stock touched a low of $5.90 on the gap move.

  The stock then worked higher the rest of the day to regain some of its deficit.

   In after-hours trading the stock was up 49 cents a share.

   Tape Action

  CNCE's tape action shows the recent block trades.

  One can see the price for the blocks falling to $5 on 50,000 shares in the morning.

  The stock then worked higher the rest of the day.


  CNCE is a biopharmaceutical company.

  It is focused on applying its DCE Platform to create novel small molecule drugs.

 The company makes drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism.


  For 2020, the Street predicts a loss of $2.55 a share compared with a loss of $3.29 the prior year.

  Looking to 2021, analysts expect a loss of $2.53 a share.

  For the first quarter, they see a loss of 61 cents a share compared with a loss of 70 cents the prior year.


  CNCE's daily chart shows the stock with a big gap drop cutting below key support.

  The stock peaked at $30 back in 2017. It has been trending lower. It did well last year, but now is rolling over.

Strategy Opinion: TTD  is targeting CNCE for a decline to $5.50.  A protective stop buy can be placed near $8

Suitability:  Aggressive Bears.

  TTD's Stock Probability research of Prior Performance:  

Response to Net


 CNCE rose 6 times after 15 earnings reports.

Seasonal Success


 CNCE lost 5.5% in Feb., rose 18% in March prior years.

Earnings Beats


 CNCE beat Street estimate 12 times after 20 reports.

   TTD's Quality Rating of Stock  - CNCE -  BELOW AVERAGE

   Stock's Performance Chart with Quarterly Earnings Markers vs. S&P 500

Insider Buying in Green  - Insider Selling in Red


   TTD takes no responsibility for trading by those using this information. The stocks presented in our report are those we deem the best looking "Day Trades" for the long side. We take no responsibility for the accuracy of this data, although every effort is made to present the information correctly. Copyright Ticker Tape Digest. - 2021

    TTD columnist Leo Fasciocco has covered the stock market for over 30 years. His articles appear in many publications. He has also been  a speaker at the Money Show conferences. He has been on television and radio. He is author of many educational articles about stock investing and the book “Guide To High-Performance Investing.”

{short description of image}

   For information to subscribe to the Ticker Tape Digest Services call: Beverly Owen at 1-480-878-8381.

   Distributed by Corona Publishing Enterprises. TickerTape Digest Inc. 1220 W. Sherri, Gilbert, Az. 85233.

  TTD “Professional Report” is available on the Web: $100 per month. Password needed. Published daily - around 20 times a month.  

 TTD Pro Report includes a Morning chart slide show of breakout stocks, a Midsession video-audio show with commentary on breakout stocks and shorts and a Final end of day overall report on breakout stocks for the session, short plays and accumulation plays.  There are other features too such as Quick Trades and Long-term Plays.  

TTD Daily Report is $39. It covers a Morning slide show of charts of stocks breaking out and a TTD end of day print report covering breakout stocks and shorts.

 Credit cards accepted. Payable to Corona Publishing Enterprises.

(The information contained has been prepared from data deemed reliable but there is no guarantee of complete accuracy. Ticker Tape Digest Inc. is not affiliated with any broker, dealer or investment advisor. Nothing in this publication constitutes an offer, recommendation or solicitation to buy or sell any securities. Further research is advised. This report is copyrighted and no redistribution is permitted with out permission.)